CD8A and pancreatic neoplasm: The efficacy of ruxolitinib therapy could be enhanced by using it as an adjunct agent to suppress chronic inflammation and facilitate infiltration of CD8+ T cells, rather than as a monotherapeutic agent for overcoming anti-PD-L1 immunotherapy resistance in pancreatic cancer patients [144].